Concept Richtlijn Erfelijke darmkanker 2007 versie 7 - Oncoline

6. Cruz-Correa M, Giardello FM. Familial adenomatous polyposis. Gastrointest Endosc2003;58:885-94.7. Dekker E, Dees J, Mathus-Vliegen L, Poley JW, Offerhaus J, Bartelsman J et al. Highresolutionendoscopy and the additional values of chromo-endoscopy in the evaluation ofduodenal polyposis in FAP-patients. Abstract NVGE voorjaarsvergadering 2006.8. Gallagher MC, Phillips RKS, Bulow S. Surveillance and management of uppergastrointestinal disease in Familial Adenomatous Polyposis. Fam Cancer 2006;5:263-73.9. Gallagher MC, Shankar A, Groves CJ, Russel RC, Phillips RK. Pylorus-preservingpancreaticoduodenectomy for advanced duodenal disease in familial adenomatousduodenal polyposis. Br J Surg 2004; 91:1157-64.10. McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: asystematic review of the observational studies of selective and nonselective inhibitors ofcyclooxygenase. JAMA 2006;296:1633-44.11. Graham DJ, Campen D, Hui R, Spence M, Cheetham C, Levy G et al. Risk of acutemyocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-controlstudy. Lancet 2005;365:475-81.12. Groves CJ, Saunders BP, Spigelman AD, Phillips RK. Duodenal cancer in patients withfamilial adenomatous polyposis (FAP): results of a 10 year prospective study. Gut2002;50:636-41.13. Han J, Kim MH. Technical review: Endoscopic papillectomy for adenomas of the majorduodenal papilla. Gastrointest Endosc 2006;633:292-301.14. Heiskanen I, Kellokumpu I, Järvinen H. Management of duodenal adenomas in 98patients with Familial Adenomatous Polyposis. Endoscopy 1999;31:412-16.15. Hirota WK, Zuckerman MJ, Adler DG. ASGE Guideline: The role of endoscopy in thesurveillance of premalignant conditions of the upper GI tract. Gastrointest Endosc2006;63:570-80.16. Juni P, Nartey L, Reichenbach S, Sterchi R, Dieppe PA, Egger M. Risk of cardiovascularevents and rofecoxib: cumulative meta-analysis. Lancet 2004;364:2021-9.17. Latchford A, Gallagher M, Newton D et al. Therapeutic endoscopy for duodenaladenomatosis in familial adenomatous polyposis. Abstract DDW 200618. Neoptolemos JP, Russell RC, Bramhall S, Theis B. Low mortality following resection forpancreatic and periampullary tumours in 1026 patients: UK survey of specialistpancreatic units. UK Pancreatic Cancer Group. Br J Surg 1997;84:1370-6.19. Nielsen M, Poley JW, Verhoef S, Puijenbroek M, Weiss MM, Burger GT et al. Duodenalcarcinoma in MUTYH-associated polyposis. J Clin Pathol 2006;59:1212-5.20. Norton ID, Geller A, Petersen BT, Sorbi D, Gostout CJ. Endoscopic surveillance andablative therapy for periampullary adenomas. Am J Gastroenterol 2001;96:101-106.21. Nugent KP, Farmer KC, Spigelman AD, Williams CB, Phillips RK. Randomized controlledtrial of the effect on duodenal and rectal polyposis and cell proliferation in patients withfamilial adenomatous polyposis. Br J Surg 1993;80:1618-9.22. Phillips RK, Wallace MH, Lynch PM, Hawk E, Gordon GB, Saunders BP et al. Arandomized, double blind, placebo controlled study of celecoxib, a selectivecyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis.Gut 2002;50:857-60.23. Richard CS, Berk T, Bapat BV, Haber G, Cohen Z, Gallinger S. Sulindac forperiampullary polyps in FAP patients. Int J Colorectal Dis 1997;12:14-8.24. Saurin JC, Ligneau B, Ponchon T, Lepretre J, Chavaillon A, Napoleon B et al. Theinfluence of mutation site and age on the severity of duodenal polyposis in patients withfamilial adenomatous polyposis. Gastrointest Endosc 2002;55:342-7.Concept landelijke richtlijn erfelijke darmkanker versie 7 d.d. 7 november 2007.108